Moderna Analyst Projects Transformation Into ‘Five-Product Commercial Company’ By 2026
Moderna Inc (NASDAQ: MRNA) is back in focus as it is making advancements in cancer treatment.
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain.
Galiano Gold’s Promising Future Post-Asanko Mine Deal: Analyst Upgrades Stock
BMO Capital Markets analyst Raj Ray upgraded Galiano Gold Inc. (AMEX: GAU) to Outperform from Market Perform,
Small Cap Restaurant Stocks On Sale: 4 Stocks To Buy For 2024, 2 To Avoid
A look at six restaurant stocks from a leading sector analyst and which four are attractive for 2024.
Glaukos’ Newly Approved Glaucoma Treatment Is The ‘Biggest Driver To Watch’: Analyst
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.
KeyCorp Gets Analyst Upgrade Due To Superior Balance Sheet, Net Interest Income
Shares of KeyCorp (NYSE: KEY) have climbed steadily over the past month.
Real Estate Company Newmark Upgraded: Analyst Highlights Strong Leasing And Capital Markets Growth In 2024
Piper Sandler analyst Alexander Goldfarb upgraded the rating on Newmark Group Inc (NASDAQ: NMRK) to Overweight from Neutral at an increased
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space.
FY24 Election Is A Major Game Changer For US Renewable Sector: Piper Analyst
Piper Sandler analyst Kashy Harrison revised the rating on several Renewables & Alternative Energy companies.
The analyst sees benefits accruing to the installers initially (FY24) and inverters eventually (FY25), with the rest of the stock in the coverage benefiting in the long term.
AIG’s Resilient Hyperinflation Strategy Leads To Analyst Upgrade
Shares of American International Group Inc (NYSE: AIG) have climbed almost 20% over the past six months.